Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr 3;5(179):179ps7.
doi: 10.1126/scitranslmed.3005568.

Cell-based therapeutics: the next pillar of medicine

Michael A Fischbach  1 , Jeffrey A Bluestone, Wendell A Lim
Affiliations

Cell-based therapeutics: the next pillar of medicine

Michael A Fischbach et al. Sci Transl Med. .

Abstract

Two decades ago, the pharmaceutical industry-long dominated by small-molecule drugs-was revolutionized by the the advent of biologics. Today, biomedicine sits on the cusp of a new revolution: the use of microbial and human cells as versatile therapeutic engines. Here, we discuss the promise of this "third pillar" of therapeutics in the context of current scientific, regulatory, economic, and perceptual challenges. History suggests that the advent of cellular medicines will require the development of a foundational cellular engineering science that provides a systematic framework for safely and predictably altering and regulating cellular behaviors.

PubMed Disclaimer

Conflict of interest statement

Competing interests: M.A.F. is on the Scientific Advisory Board of Second Genome. W.A.L. is on the Scientific Advisory Board of Cambrian Genomics.

Figures

Fig. 1
Fig. 1. Killer apps
Although small molecules and biologics will always have important therapeutic niches, there are numerous applications for which cells are better equipped. Four killer applications for cell-based therapeutics are shown: immune cells engineered to recognize and kill tumor cells, transplanted microbiota that detect and treat intestinal inflammation (e.g., Crohn’s disease) by producing an anti-inflammatory small molecule or biologic, a combination bacterial/mammalian cell therapeutic in which the bacterial cell converts dietary sugars into a nonabsorbed fermentation product and activates the production of a satiety-inducing hormone by the companion human cell therapeutic, and patient-specific stem cells for regenerative medicine [not discussed herein, but see (13)]. iPSCs, induced pluripotent stem cells.
Fig. 2
Fig. 2. Evolution and (beyond) tinkering
The sustainable growth of a cell-based-therapeutic industry requires the evolution of a foundational science of cellular engineering. Fundamental knowledge and capabilities developed by cellular engineering scientists will allow us to move beyond tinkering toward systematic mechanisms for predictable modulation of cell proliferation, migration, communication, and the production of small molecules and biologics.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mason C, Brindley DA, Culme-Seymour EJ, Davie NL. Cell therapy industry: Billion dollar global business with unlimited potential. Regen Med. 2011;6:265–272. - PubMed
    1. Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, Defor T, Levine BL, June CH, Rubinstein P, McGlave PB, Blazar BR, Wagner JE. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: Safety profile and detection kinetics. Blood. 2011;117:1061–1070. - PMC - PubMed
    1. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725–733. - PMC - PubMed
    1. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: Harnessing the T cell response. Nat Rev Immunol. 2012;12:269–281. - PMC - PubMed
    1. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407–415. - PubMed

Publication types